Clinical Trials Browser

Leukemia, Myelodysplastic Syndromes

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

High Grade Serous Carcinoma

Prostatic Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Osteosarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Fallopian Tube Neoplasms, Ovarian Neoplasms

Extensive Stage Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Non Small Cell Lung Cancer NSCLC

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Solid Tumour Refractory to Conventional Treatment

Carcinoma, Non-Small-Cell Lung

Bile Duct Neoplasms

Bile Duct Neoplasms

Small Cell Lung Carcinoma

Neoplasm Metastasis, Neoplasms

Advanced Breast Cancer

Clinical Trials

AZD6738 for Patients With Progressive MDS or CMML

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

CAPRI

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

ESMART

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

CONCORDE

AUSTRAL

ATRiBRAVE

PHOENIX

Patriot

PIONeeR

AZD6738 Plus Durvalumab in Biliary Tract Cancer

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

SUKSES-N4

OLAPCO

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

ATRiUM

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

plasmaMATCH